Stockwatch: When more is much less
This article was originally published in Scrip
Life is full of paradoxes. Many of the world's highest paid soccer players come to work in Europe where sovereign debt defaults abound, and in Spain specifically, which has just been bailed out to the tune of €100 billion by the Eurozone stability facilities. At least those with the least money are now able to pay those with the most.
You may also be interested in...
AbbVie’s latest, largest acquisition may be cast in a new light as the pandemic throws stock markets into turmoil and commercial prospects up in the air.
The prices of biotechnology and pharmaceutical sector indices continue to be comparatively robust in the face of big falls in global markets as investors expect new drugs and vaccines to be generated by the sector. While it is largely accepted that the life science sector will eventually ride to the rescue, bumper profits are far from guaranteed.
Pharmaceutical shares are stronger than most as world stock markets dive downwards, but they are not immune to the coronavirus fallout. The effects will be felt by biopharma companies across many areas of their activity.